The stock of Astrazeneca plc ADR (AZN) has gone up by 2.02% for the week, with a 5.94% rise in the past month and a 4.44% rise in the past quarter. The volatility ratio for the week is 1.00%, and the volatility levels for the past 30 days are 1.24% for AZN. The simple moving average for the last 20 days is 3.47% for AZN’s stock, with a simple moving average of 5.25% for the last 200 days.
Is It Worth Investing in Astrazeneca plc ADR (NASDAQ: AZN) Right Now?
Astrazeneca plc ADR (NASDAQ: AZN) has a higher price-to-earnings ratio of 36.74x compared to its average ratio. AZN has 36-month beta value of 0.52. Analysts have mixed views on the stock, with 1 analysts rating it as a “buy,” 3 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for AZN is 3.10B, and currently, short sellers hold a 0.25% ratio of that float. The average trading volume of AZN on April 22, 2024 was 6.25M shares.
AZN) stock’s latest price update
The stock price of Astrazeneca plc ADR (NASDAQ: AZN) has jumped by 2.29 compared to previous close of 68.55. Despite this, the company has seen a gain of 2.02% in its stock price over the last five trading days. InvestorPlace reported 2024-04-19 that Inflation in the United States has been stubborn and a matter of concern for policymakers. For March, the consumer price increase rose by 3.5% on a year-on-year basis, which was more than expected.
Analysts’ Opinion of AZN
Morgan Stanley gave a rating of “Overweight” to AZN, setting the target price at $85 in the report published on January 23rd of the current year.
AZN Trading at 6.05% from the 50-Day Moving Average
After a stumble in the market that brought AZN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -8.41% of loss for the given period.
Volatility was left at 1.24%, however, over the last 30 days, the volatility rate increased by 1.00%, as shares surge +5.66% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +10.22% upper at present.
During the last 5 trading sessions, AZN rose by +1.86%, which changed the moving average for the period of 200-days by +7.03% in comparison to the 20-day moving average, which settled at $67.95. In addition, Astrazeneca plc ADR saw 4.11% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for AZN
Current profitability levels for the company are sitting at:
- 0.18 for the present operating margin
- 0.82 for the gross margin
The net margin for Astrazeneca plc ADR stands at 0.13. The total capital return value is set at 0.12. Equity return is now at value 15.63, with 6.03 for asset returns.
Based on Astrazeneca plc ADR (AZN), the company’s capital structure generated 0.42 points at debt to capital in total, while cash flow to debt ratio is standing at 0.36. The debt to equity ratio resting at 0.73. The interest coverage ratio of the stock is 5.13.
Currently, EBITDA for the company is 13.91 billion with net debt to EBITDA at 1.8. When we switch over and look at the enterprise to sales, we see a ratio of 5.24. The receivables turnover for the company is 3.38for trailing twelve months and the total asset turnover is 0.45. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.82.
Conclusion
To put it simply, Astrazeneca plc ADR (AZN) has had a better performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
